Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL)

NCT04276870 is registered in ClinicalTrials.gov with Stephan Grupp MD PhD as lead sponsor.

NCT NCT04276870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04276870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL)
Lead sponsor
Stephan Grupp MD PhD
Phase
Phase 2
Overall status
Recruiting
Start date
March 12, 2020
Completion date
March 10, 2037
Enrollment
133 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infants with very high risk kmt2a b-all, patients with central nervous system relapse who did not receive cranial radiation or bone marrow transplantation, pediatric and young adult patientswith hypodiploid or t(17;19) b-all